Phase IIB Insomnia Trial Complete
Our cannabis drug development company BOD Science (ASX:BOD) announced it had completed its Phase IIB insomnia trial on its CBD formulation, which was conducted by the Woolcock Institute of Medical Research.
That means the last patient has completed the study - now we are looking for results.
Topline results are expected late August, which if positive, BOD intends to take to the Therapeutic Goods Administration (TGA) via a dossier which could form the basis of an Australian first - a Schedule 3 CBD product.
This could increase the availability of BOD’s CBD formulation to a wider swathe of the population and underpin greater sales for the company.
We note that while we expected results from this trial in late June, we are cognizant that trials can take longer than expected sometimes.
We are looking forward to these topline results as it could form one of two important potential catalysts for BOD as it advances a pipeline of products.
What’s next for BOD?
🔄 Results from the Phase IIb clinical trial using BOD’s CBD (Cannabidiol) product on insomnia
As above, unlock the opportunity for significant sales for the first “over-the-counter” cannabis products in Australia. We think media attention would likely follow as this would be the first time this has happened in Australia. We recently saw that in late June Australia became the first country in the world to legalise the use of psychedelics to treat some mental health conditions. We think this could be a leading indicator that the regulatory environment is easing in Australia.
🔄 PK Study results and Aqua Phase acquisition complete
The results from these two Pharmacokinetic (PK) Studies evaluate how well BOD’s tech can improve absorption of CBD (also known as bioavailability). A material improvement in bioavailability would have major implications for BOD. It opens up the potential to licence/or form partnerships across the whole global CBD market, a US$6BN industry that would be eager to get access to this tech.
